Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.
Oncology, Medical September 19th 2023
Roswell Park
Discover how Roswell Park’s phase 2 clinical trials are exploring the potential of propranolol to enhance the efficacy of immunotherapies in treating esophageal cancer. This could represent a significant shift in treatment protocols.
Renal & Urology News
New data suggests that intensifying neoadjuvant therapy with abiraterone or docetaxel could significantly improve outcomes in very high-risk prostate cancer patients. Explore the full findings to consider how this could impact your treatment approach.
OBR Oncology
New data from the FLAURA2 trial suggests a promising but complex treatment landscape for EGFR-mutated advanced NSCLC. Physicians should weigh the significant PFS benefits against the increased risk of adverse events before considering this combination as a first-line treatment option.